Glenmark Pharmaceuticals has informed about a Press Release dated April 26, 2016 titled ‘Glenmark Pharmaceuticals receives tentative ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.01 mg, Ethinyl Estradiol Tablets USP, 0.01 mg and Ferrous Fumarate Tablets, 75 mg’.
The above information is a part of company’s filings submitted to BSE.